Fresenius Kabi has announced that it has received approval from the U.S. Food and Drug Administration to market Naropin (ropivacaine HCL Injection, USP) 0.2 percent 100mL and 200mL premix bags in the company’s proprietary Freeflex delivery system. These new presentations are available now for U.S. customers.
Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition.
“We introduced Naropin in Freeflex containers to give clinicians more choices and greater convenience in treating patients requiring continuous epidural infusions or local infiltration,” said John Ducker, president and CEO of Fresenius Kabi USA.
Fresenius Kabi offers the broadest ropivacaine portfolio, providing the most options for patient care in surgical anesthesia, labor and delivery, and acute pain management. In addition to the new 0.2 percent Freeflex bags, Naropin is available in multiple presentations including single-dose vials, plastic ampule sterile-paks, and infusion bottles in four different strengths – 0.2 percent, 0.5 percent, 0.75 percent and 1 percent.
Freeflex is a bag designed for infusion solutions that has been marketed globally since 2005 and in the U.S. since 2008. Freeflex’s multilayer polyolefin film is non-PVC and non-DEHP that is designed for easy handling with enhanced safety and environmental performance in mind.
